Financial Personal
Onc.AI Serial Imaging Response Score Outperforms Traditional Methods for Early Assessment of NSCLC Immunotherapy Outcomes
Multi-institutional study presented at the SITC annual meeting highlights the ability of Onc.AI’s imaging-based biomarker to improve identification of long-term survivors at first follow up (HR 0.33). SAN CARLOS, Calif. & WATERLOO, Ontario ̵
Multi-institutional study presented at the SITC annual meeting highlights the ability of Onc.AI’s imaging-based biomarker to improve identification of long-term survivors at first follow up (HR 0.33). Read More
